Company / Total Assets
Seres Therapeutics, Inc. Total Assets History
FY2015-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Total Assets
$138.2M
FY2025
5-year range
$138.2M / $354.9M
FY2021-FY2025
Trend
-60.4%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Total Assets has fluctuated over the past 10 years, ranging from $120M in FY2018 to $355M in FY2021.
Based on SEC 10-K filings.
$138M in FY2025 with a 10-year CAGR of -4.4%.
Declined from $349M to $138M over the past 3 years.
Total Assets over time
Growth rates
- 3-Year CAGR
- -26.6%
- 5-Year CAGR
- -16.6%
- 10-Year CAGR
- -4.4%
Key checks
Key Insights
- 5-year CAGR of -16.6%, indicating a declining trend.
- In FY2025, total assets decreased 60.4% year-over-year.
- Peak total assets was recorded in FY2021.
- Lowest total assets in the period was in FY2018.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -4.18 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Total AssetsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $138.2M | -60.4% |
| FY2023 | $348.8M | +0.0% |
| FY2022 | $348.8M | -1.7% |
| FY2021 | $354.9M | +3.5% |
| FY2020 | $342.9M | +158.9% |
| FY2019 | $132.4M | +9.9% |
| FY2018 | $120.5M | -36.4% |
| FY2017 | $189.5M | -30.5% |
| FY2016 | $272.6M | +25.7% |
| FY2015 | $216.9M | - |
As of FY2025 · SEC Form 10-K · Last checked Jun 24, 2026